Novartis’ Canakinumab Just Can’t Get the Magic Back By Sam | October 25, 2021 For the second time, Novartis’ workhorse anti-inflammatory, Ilaris (canakinumab), has failed to prove its mettle as an anti-cancer agent. Source: Drug Industry Daily Posted in Drug Industry Daily